Pharsight

Drugs that contain Sotagliflozin

1. Inpefa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7781577 LEXICON PHARMS INC Inhibitors of sodium glucose co-transporter 2 and methods of their use
May, 2028

(3 years from now)

US8476413 LEXICON PHARMS INC Sulfanyl-tetrahydropyran-based compounds and methods of their use
May, 2028

(4 years from now)

US8217156 LEXICON PHARMS INC Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2028

NCE-1 date: 27 May, 2027

Market Authorisation Date: 26 May, 2023

Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...

Dosage: TABLET;ORAL

More Information on Dosage

INPEFA family patents

Family Patents